Compare XOM & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XOM | MRK |
|---|---|---|
| Founded | 1870 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.4B | 317.8B |
| IPO Year | 2026 | 1995 |
| Metric | XOM | MRK |
|---|---|---|
| Price | $159.96 | $130.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 17 |
| Target Price | ★ $153.54 | $125.59 |
| AVG Volume (30 Days) | ★ 10.6M | 6.1M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | 2.66% | ★ 3.06% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ 4.47 | N/A |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | $16.41 | $3.61 |
| Revenue Next Year | N/A | $5.41 |
| P/E Ratio | $35.67 | ★ N/A |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $105.67 | $77.58 |
| 52 Week High | $176.41 | $135.05 |
| Indicator | XOM | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 64.52 | 58.12 |
| Support Level | $144.72 | $112.68 |
| Resistance Level | $163.68 | $131.02 |
| Average True Range (ATR) | 3.53 | 3.06 |
| MACD | 0.24 | -0.21 |
| Stochastic Oscillator | 84.18 | 48.13 |
ExxonMobil is an integrated oil and gas company that explores for, produces, and refines oil worldwide. In 2025, it produced 3.3 million barrels of liquids and 8.4 billion cubic feet of natural gas per day. At the end of 2025, reserves were 19.3 billion barrels of oil equivalent, 69% of which were liquids. The company is one of the world's largest refiners, with a total global refining capacity of 4.1 million barrels of oil per day, and is one of the world's largest manufacturers of commodity and specialty chemicals.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).